FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN) today announced an agreement granting Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a national leader in clinical laboratory testing, rights to represent and offer Vyteris’ LidoSite®, the first FDA-approved active transdermal smart patch for relief from pain associated with venipunctures and blood draws among certain patients. The agreement allows LabCorp to make LidoSite available for outpatient use to physician offices nationally.
